ClinicalTrials.gg
CompletedNCT01980628Updated Oct 16, 2019Results posted

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

A Phase 2 interventional study of ibrutinib in Marginal Zone Lymphoma and B-cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-16.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing ibrutinib in Lymphoma, B-Cell, Marginal Zone — none open to participants now, 3 under way, none of them phase 3. ibrutinib · Lymphoma, B-Cell, Marginal Zone.

Enrollment
6th of 13
63 · median 48
Started
2013
with 1 other
Phase 2
5 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
2 of 13
Pharmacyclics LLC.

Among the 13 studies testing ibrutinib in Lymphoma, B-Cell, Marginal Zone, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 2, and was the 5th registered.

Lymphoma, B-Cell, Marginal Zone

875 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 111 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

None of the 13 studies testing ibrutinib in Lymphoma, B-Cell, Marginal Zone is open now. The open studies under Lymphoma, B-Cell, Marginal Zone, anywhere →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 77 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ibrutinib in Lymphoma, B-Cell, Marginal Zone as a file.
02

Study summary

Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).

Read the detailed description

Ibrutinib is a first-in-class, potent, orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK). Inhibition of BTK blocks downstream B-cell receptor (BCR) signaling pathways and thus prevents B-cell proliferation. In vitro, ibrutinib inhibits purified BTK and selected members of the kinase family with 10-fold specificity compared with non-BTK kinases. Phase 1 and 2 studies of ibrutinib in B-cell malignancies demonstrate modest toxicity and significant single agent activity in a variety of B-cell malignancies, including NHL.

03

Conditions studied

  • Marginal Zone Lymphoma
  • B-cell Lymphoma

Keywords

  • MZL
  • NHL
  • SMZL
  • NMZL
  • MALT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • documented marginal zone lymphoma including splenic, nodal, and extranodal sub-types; subjects with splenic MZL must have an additional , nodal or extranodal, as described in inclusion criteria 5
  • Previously received one or more including at least one CD20-directed regimen (either as monotherapy or as chemoimmunotherapy) with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen
  • Men and women ≥18 years of age
  • performance status of ≤2
  • ≥1 measurable lesion site on CT scan (>1.5 cm in longest dimension). Lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by MRI instead. (Subjects with spleen-only disease are considered as not having measurable disease.)
  • of >3 months, in the opinion of the investigator

Key Exclusion criteria:

  • Medically apparent CNS lymphoma or
  • History of other except adequately treated non melanoma skin cancer, curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for ≥2 years
  • History of allogeneic stem-cell (or other organ) transplantation
  • Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within 21 days of the first dose of study drug
  • Any external beam radiation therapy within 6 weeks prior to the first dose of the study drug
  • Concurrent use of warfarin or other vitamin K antagonists
  • Concurrent use of a strong inhibitor. Subjects who have received a strong CYP3A inhibitor prior to entering the study must have discontinued therapy for at least 5 half lives of the prohibited medication.
  • Recent infection requiring IV anti-infective treatment that was completed ≤14 days before the first dose of study drug
  • Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Grade 0 or 1, or to the levels dictated in the eligibility criteria with the exception of alopecia
  • Inadequate organ function as defined on laboratory tests
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    ibrutinib

    ibrutinib capsules: 560 mg once daily

    Drug: ibrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. ORR (Overall Response Rate)

    ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC). Per Cheson: CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites.

    Time frame: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

Secondary outcomes

  1. DOR (Duration of Response)

    The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause.

    Time frame: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.

07

Results

Posted Feb 10, 2017

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib
Started63
Completed0
Not completed63
Withdrew: Adverse event12
Withdrew: Physician decision5
Withdrew: Withdrawal by subject4
Withdrew: Pd, subj non-compliant,study terminated42

Outcome measures

PrimaryORR (Overall Response Rate)

ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC). Per Cheson: CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites.

Time frame:
Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Reported as:
Mean · Percentage of Participants
ORR (Overall Response Rate)
Percentage of ParticipantsSingle Arm, Intent to Treat Population
ORR (Overall Response Rate)46 (33.5 to 59.3)
SecondaryDOR (Duration of Response)

The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause.

Time frame:
Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
Reported as:
Median · Months
DOR (Duration of Response)
MonthsIbrutinib
DOR (Duration of Response)NA (16.7 to NA)

Adverse events

Collected over From the time of first ibrutinib dose until 30 days following the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib17/63 (27%)29/63 (46%)63/63 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventIbrutinib
PneumoniaInfections and infestations5/63
Autoimmune Haemolytic AnaemiaBlood and lymphatic system disorders2/63
CellulitisInfections and infestations2/63
SepsisInfections and infestations2/63
Haemolytic AnaemiaBlood and lymphatic system disorders1/63
Atrial FibrillationCardiac disorders1/63
Pericardial EffusionCardiac disorders1/63
PancreatitisGastrointestinal disorders1/63
StomatitisGastrointestinal disorders1/63
AstheniaGeneral disorders1/63
Most frequent other events
Showing 10 of 80
Most frequent other events
EventIbrutinib
DiarrhoeaGastrointestinal disorders30/63
FatigueGeneral disorders29/63
AnaemiaBlood and lymphatic system disorders23/63
NauseaGastrointestinal disorders20/63
Upper Respiratory Tract InfectionInfections and infestations16/63
CoughRespiratory, thoracic and mediastinal disorders16/63
ThrombocytopeniaBlood and lymphatic system disorders15/63
Oedema PeripheralGeneral disorders15/63
ArthralgiaMusculoskeletal and connective tissue disorders15/63
DizzinessNervous system disorders14/63

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ibrutinib
<=18 years0
Between 18 and 65 years27
>=65 years36
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib
Female37
Male26
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ibrutinib
White53
Black6
Asian1
Unknown3
08

Study locations

25 sites
  • Site Reference ID/Investigator# 837
    Tucson, Arizona 85719, United States
  • Site Reference ID/Investigator# 047
    Duarte, California 91010, United States
  • Site Reference ID/Investigator# 377
    Santa Monica, California 90095, United States
  • Site Reference ID/Investigator# 763
    West Palm Beach, Florida 33401, United States
  • Site Reference ID/Investigator# 033
    Atlanta, Georgia 30322, United States
  • Site Reference ID/Investigator# 370
    Chicago, Illinois 60611, United States
  • Site Reference ID/Investigator# 195
    Detroit, Michigan 48202, United States
  • Site Reference ID/Investigator# 350
    New Hyde Park, New York 11042, United States
  • Site Reference ID/Investigator# 745
    New York, New York 08724, United States
  • Site Reference ID/Investigator # 200
    New York, New York 10065, United States
  • Site Reference ID/Investigator # 407
    New York, New York 10065, United States
  • Site Reference ID/Investigator# 220
    Hershey, Pennsylvania 17033, United States
  • Site Reference ID/Investigator# 348
    Seattle, Washington 98109, United States
  • Site Reference ID/Investigator# 560
    Ghent, Oost-vlaanderen, Belgium
  • Site Reference ID/Investigator# 737
    Rouen Cedex 1, Haute-normandie, France
  • Site Reference ID/Investigator# 735
    Paris Cedex 10, Ile-de-france, France
  • Site Reference ID/Investigator# 750
    Lille Cedex, NORD Pas-de-calais, France
  • Site Reference ID/Investigator# 749
    La Roche-sur-Yon Cedex 9, PAYS DE LA Loire, France
  • Site Reference ID/Investigator# 736
    Nantes cedex 1, PAYS DE LA Loire, France
  • Site Reference ID/Investigator# 142
    Pierre Bénite Cedex, Rhone-alpes, France
  • Site Reference ID/Investigator# 742
    Rennes cedex 9, France
  • Site Reference ID/Investigator# 669
    Mainz, Rheinland-Pfalz, Germany
  • Site Reference ID/Investigator# 030
    Manchester, England, United Kingdom
  • Site Reference ID/Investigator# 814
    Oxford, England, United Kingdom
  • Site Reference ID/Investigator# 368
    Plymouth, England, United Kingdom
09

References and documents

Publications

  • Noy A, de Vos S, Coleman M, Martin P, Flowers CR, Thieblemont C, Morschhauser F, Collins GP, Ma S, Peles S, Smith SD, Barrientos JC, Chong E, Wu S, Cheung LW, Kwei K, Hauns B, Arango-Hisijara I, Chen R. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020 Nov 24;4(22):5773-5784. doi: 10.1182/bloodadvances.2020003121. PubMed 33227125 ↗
  • Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. PubMed 28167659 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jul 2016 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2013
First posted
Nov 11, 2013
Start
Dec 2013
Primary completionActual
Jul 2016
CompletionActual
Oct 2, 2017
Results first posted
Feb 10, 2017
Last update
Oct 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01980628
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Dec 2013
Primary completion
Jul 2016
Completion
Oct 2, 2017
Results posted
Feb 10, 2017
Last update
Oct 16, 2019

Study contacts

Isaiah Dimery, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion